T he licensing of β-interferons for the treatment of multiple sclerosis (MS) has created a dilemma for the UK National Health Service (NHS). There is now a therapy available for a disease where management has traditionally been limited to symptomatic treaments; however, it comes with a large price tag attached. At a time when rationing is becoming a reality in the NHS, how has the issue of β-interferon prescribing been handled and how are patients with MS faring? Delegates at a recent British Association of Pharmaceutical Physicians meeting* heard from representatives of 2 parties involved in this debate - the pharmaceutical industry and patients.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
* ‘Is the pharmaceutical industry providing the NHS with medicines it can afford?’ [London, UK; 31 March 1999]
About this article
Cite this article
Wright, T. UK debate over β-interferon prescribing continues. Pharmacoecon. Outcomes News 217, 3–5 (1999). https://doi.org/10.1007/BF03280113
- Multiple Sclerosis
- Multiple Sclerosis Patient
- National Health Service
- Multiple Sclerosis Population